The effect of ticagrelor monotherapy on platelet reactivity
- Conditions
- Circulatory SystemCoronary artery disease and ischaemic heart disease
- Registration Number
- ISRCTN84335288
- Lead Sponsor
- niversity Hospitals Bristol NHS Foundation Trust
- Brief Summary
2017 protocol in: https://www.ncbi.nlm.nih.gov/pubmed/29121979 2020 results in https://pubmed.ncbi.nlm.nih.gov/33305660/ (added 14/12/2020)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 110
1. Patient is treated with dual antiplatelet therapy comprising aspirin and clopidogrel for a minimum of 4 weeks (amended from: for 12 months as of 31/03/2016)
2. The patient is scheduled to stop dual antiplatelet therapy and continue with aspirin monotherapy
1. Contraindication to dual antiplatelet therapy
2. Interruption of dual antiplatelet therapy because of bleeding events or increased bleeding risk
3. Contraindications to the use of ticagrelor
4. Pregnant and or lactating women
5. Women with child bearing potential (i.e. not sterilised or not post-menopausal) who are unwilling to use contraception
6. Men with a spouse or partner with child bearing potential unless the participant has agreed to use condoms
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> Maximum amplitude of the light transmission aggregation response of platelet rich plasma (PRP) to 10 µM TRAP expressed as a % of the absolute difference in light transmission between PRP and platelet poor plasma. This assay measures the ability of platelets to aggregate when exposed to the aggregation promoting agent TRAP.<br><br> Measured at each visit, i.e. at visit 1 (baseline visit), at visit 2 (4 weeks after the baseline visit), and at visit 3 (8 weeks after the baseline visit).<br>
- Secondary Outcome Measures
Name Time Method